Abstract
GABAergic inhibition in the brain can be classified as either phasic or tonic. gamma-Aminobutyric acid (GABA) uptake by GABA transporters (GATs) can limit the time course of phasic currents arising from endogenous and exogenous GABA, as well as decrease a tonically active GABA current. GABA transporter subtypes 1 and 3 (GAT-1 and GAT-3) are the most heavily expressed of the four known GAT subtypes. The role of GATs in shaping GABA currents in the neocortex has not been explored. We obtained patch-clamp recordings from layer II/III pyramidal cells and layer I interneurons in rat sensorimotor cortex. We found that selective GAT-1 inhibition with NO711 decreased the amplitude and increased the decay time of evoked inhibitory postsynaptic currents (IPSCs) but had no effect on the tonic current or spontaneous IPSCs (sIPSCs). GAT-2/3 inhibition with SNAP-5114 had no effect on IPSCs or the tonic current. Coapplication of NO711 and SNAP-5114 substantially increased tonic currents and synergistically decreased IPSC amplitudes and increased IPSC decay times. sIPSCs were not resolvable with coapplication of NO711 and SNAP-5114. The effects of the nonselective GAT antagonist nipecotic acid were similar to those of NO711 and SNAP-5114 together. We conclude that synaptic GABA levels in neocortical neurons are controlled primarily by GAT-1, but that GAT-1 and GAT-2/3 work together extrasynaptically to limit tonic currents. Inhibition of any one GAT subtype does not increase the tonic current, presumably as a result of increased activity of the remaining transporters. Thus neocortical GAT-1 and GAT-2/3 have distinct but overlapping roles in modulating GABA conductances.
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
6-Cyano-7-nitroquinoxaline-2,3-dione / pharmacology
-
Analysis of Variance
-
Animals
-
Animals, Newborn
-
Anisoles / pharmacology
-
Bicuculline / pharmacology
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Radiation
-
Drug Synergism
-
Electric Stimulation / methods
-
GABA Agonists / pharmacology
-
GABA Antagonists / pharmacology
-
GABA Plasma Membrane Transport Proteins
-
In Vitro Techniques
-
Membrane Potentials / drug effects
-
Membrane Potentials / physiology
-
Membrane Potentials / radiation effects
-
Membrane Transport Modulators*
-
Membrane Transport Proteins / antagonists & inhibitors*
-
Membrane Transport Proteins / classification
-
Models, Neurological
-
Muscimol / pharmacology
-
Neocortex / cytology
-
Neocortex / physiology*
-
Neural Inhibition / drug effects
-
Neural Inhibition / physiology
-
Neural Inhibition / radiation effects
-
Neurons / classification
-
Neurons / drug effects
-
Neurons / physiology
-
Neurons / radiation effects
-
Neurotransmitter Uptake Inhibitors / classification
-
Neurotransmitter Uptake Inhibitors / pharmacology*
-
Nipecotic Acids / pharmacology
-
Oximes / pharmacology
-
Patch-Clamp Techniques / methods
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, GABA-A / physiology*
-
Time Factors
-
gamma-Aminobutyric Acid / metabolism*
Substances
-
1-(2-(tris(4-methoxyphenyl)methoxy)ethyl)-3-piperidinecarboxylic acid
-
Anisoles
-
GABA Agonists
-
GABA Antagonists
-
GABA Plasma Membrane Transport Proteins
-
Membrane Transport Modulators
-
Membrane Transport Proteins
-
Neurotransmitter Uptake Inhibitors
-
Nipecotic Acids
-
Oximes
-
Receptors, GABA-A
-
Slc6a1 protein, rat
-
NNC 711
-
nipecotic acid
-
Muscimol
-
gamma-Aminobutyric Acid
-
6-Cyano-7-nitroquinoxaline-2,3-dione
-
Bicuculline